Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Calliditas Therapeutics to participate in upcoming investor conferences

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that its management team will participate in the following upcoming investor conferences and events: · The 8[th] Annual LSX World Congress on May 10-11, 2022 in London, United Kingdom · The ABGSC Life Science Summit on May 18–19, 2022, in Stockholm, Sweden. · H.C. Wainwright Hybrid Global Investment Conference on May 23-26, 2022. · Jefferies Healthcare Conference on June 8-10, 2022 in New York City, USA. · Citi European Healthcare Conference on June 14–16, 2022 in London, United

Cary Group commits to the Science Based Targets initiative

Cary Group aims to be an industry leader when it comes to climate action. The company has, as a part of its strategy, set a high and clear objective on how to reduce its climate impact. Therefore, Cary Group commits to the Science Based Targets initiative (SBTi) as a next step to reach its reduction targets in line with the 1,5°C goal of the Paris Agreement by 2030.Cary Group has committed to set targets in line with the Science Based Targets initiative (SBTi), consistent with the Paris Agreement. This is a natural step in Cary Group’s sustainable strategy, which incorporates sustainability

2020 Bulkers Ltd. (2020) – Commercial update and key information relating to the cash distribution for April 2022

Hamilton, Bermuda, May 10, 2022   Commercial update: In April 2022, the Company achieved average time charter equivalent earnings of approximately US$23,600 per day, gross. The Company’s six vessels trading on index-linked time charter earned approximately US$20,300 per day, gross, including average daily scrubber benefits of approximately US$1,600 per day. The Company’s two vessels trading on fixed time charter earned approximately US$33,700 per day, gross, including average daily scrubber benefits of approximately US$2,300 per day.   The Baltic 5TC Capesize Index averaged

Targovax and Oslo University Hospital announce collaboration to test TG mutant RAS vaccination in multiple myeloma

· Targovax has entered into an agreement with Oslo University Hospital (OUS) to test TG01 in a phase 1/2 trial in 20 patients with RAS mutant multiple myeloma · The trial will be sponsored by OUS and led by Dr. Fredrik Schjesvold, an international leader in the field and founder of the Oslo Myeloma Center, the largest Myeloma center in the Nordics · The trial will be the first time TG vaccination is tested in patients together with the new adjuvant QS-21 STIMULON™ from collaboration partner AgenusOslo, Norway, 10 May 2022 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology

Interim report January – March 2022

First quarter in brief · Net sales amounted to 9.9 million SEK (14.7), which represents a decrease in sales of 33 percent. · Operating profit amounted to -3.6 million SEK (2.5). · Net profit for the period amounted to -3.5 million SEK (2.7). · Earnings per share amounted to -0.08 SEK (0.07).   Significant events during the first quarter During the period, a directed share issue was carried out for an amount equivalent to 60 million SEK before transaction costs. SyntheticMR US Inc has entered a partnership with Hyland Healthcare. A sales and support

Veg of Lund updates strategy and revises objectives with focus on growth

The Board of Directors of Veg of Lund AB has conducted a strategic review of the business and decided on an updated strategy and revised targets in order to increase sales. The company clarifies that the business model consists of a hybrid between own and licensed production and sales. The strategy is to accelerate sales by appointing licensees in more countries. The goal is to reach a turnover of MSEK 420 with a positive operating result by the year 2025.Veg of Lund’s current board took office after an extraordinary general meeting on 31 January 2022 and has conducted a review of the

COSEL announces 6W high isolation DC/DC converters for medical, industrial and ICT applications

•    High input/output isolation 3kVAC, 4.2kVDC•    Medical isolation 2MOOP - 250VAC working voltage•    Low input/output capacitance – 20 pF maximum•    Ultra-wide input voltage (4:1) - 4.5V to 18V ; 9V to 36V ; 18V to 76V•    Ruggedized pins connector•    Made in Japan - 5 years warranty COSEL Co, Ltd (6905: Tokyo) today announced the addition of a new series of high isolation 6W DC/DC converters for medical, industrial and ICT applications. Packaged in a Single In Line (SIP) type 8, the COSEL MH6 series has a reinforce isolation of 3kVAC, 4.2kVDC, complies with medical

Nordstjernan issues call options in Momentum Group

CEO Ulf Lilius and CFO Niklas Enmark of Momentum Group AB (publ) (“Momentum Group”) have acquired call options for shares in Momentum Group. The call options were issued on market-based terms by Momentum Group’s principal owner, Nordstjernan AB. The call options do not entail any dilution for the other shareholders. Momentum Group is not participating in the issue of the call options and will not be charged with any related costs.     Peter Hofvenstam President and CEO Nordstjernan AB     Questions will be answered by:   Peter Hofvenstam, CEO, Nordstjernan E-

Polymer Factory Sweden AB (publ) Interim Report Q1 2022

The period in summary First quarter, January-March 2022 · The Company received a strategically important order in January 2022 from a global life science company · A new Product Manager joined Polymer Factory on February 1, 2022 · An incentive program for key personnel was implemented Key Figures (KSEK) Jan-Mar Jan-Mar 2022 2021Net sales    451 783Profit (loss) for the period    -1,052 -677Total assets 10,506 15,410Equity / assets ratio (%) 91

Moberg Pharma´s Interim report January - March 2022

EUROPEAN MARKETING AUTHORIZATION APPLICATION SUBMITTED AND NORTH AMERICAN PHASE 3 STUDY STARTEDFIRST QUARTER JAN-MAR 2022 · EBITDA SEK -4.8 million (-5.4) * · Operating profit (EBIT) SEK -5.4 million (-6.1) * · Profit after tax SEK -4.4 million (-5.0) * · Total profit SEK -4,4 million (18.6) · Diluted earnings per share SEK -0.10 (0.46) * · Cash and cash equivalents amounted to SEK 73.4 million (133.6) * All comparative figures refer to continuing operations SIGNIFICANT EVENTS IN THE FIRST QUARTER · Moberg Pharma submitted a marketing authorization application

Navamedic ASA: Q1 2022 financial results

Oslo, 10 May 2022 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, grew revenues with 7.4 percent in the first quarter of 2022 compared to the same period in 2021.   “We had a solid first quarter with continued growth driven by new product launches and strong development for existing products within medical nutrition, consumer health and branded generics. Our type of business will always experience some volatility in revenue growth from quarter to quarter due to pipeline effects, and in the first

Nordic Mining ASA (EN Expand:NOM) - Interim report per 31 March 2022

Please find enclosed Nordic Mining’s interim report and company presentation for the first quarter of 2022. The interim report and company updates will be presented digitally today, Tuesday 10 May 2022 at 10.00 (CET). The presentation and Q&A session will be held in English and transferred via webcast. You will have the opportunity to post questions online throughout the webcast session. The webcast will be available on: https://channel.royalcast.com/landingpage/hegnarmedia/20220510_9/ Summary of important events in the first quarter of 2022 and year to date: KEY EVENTS ·

Karnov Group reports first quarter results 2022

Strong growth and good cash flowFINANCIAL HIGHLIGHTS First QUARTER · Net sales increased by 9.2% to SEK 255 m (234), organic growth was 4.8% and acquired growth accounted for 2.1%. Currency effect was 2.3%. · EBITA amounted to SEK 85 m (95) with EBITA margin of 33.5% (40.7%). Items affecting comparability amounted to SEK 19 m (0). · Adjusted EBITA amounted to SEK 104 m (95) with adjusted EBITA margin of 40.8% (40.7%). · Net result amounted to SEK 24 m (40), impacted by items affecting comparability of SEK 19 m (0). · Earnings per share amounted to SEK 0.23 (0.41). Earnings

Lantmännen and Spendrups in renewed partnership on sustainable cultivation methods for barley

During the spring, Lantmännen and Spendrups have initiated a new collaboration where malt barley, the main ingredient in beer, for the first time is grown according to Climate & Nature - Lantmännen's cultivation program for Farming of the Future. This means that cultivation methods that reduce climate impact and benefit biodiversity will be used. The crop is already in the soil and the malt barley is to be harvested in the fall, and then used in beer brewed in early 2023.Spendrups has been using malt barley from Lantmännen for many years. The collaboration around Lantmännen's cultivation

Read original

Etteplan supports research towards an additive manufacturing breakthrough in the Swedish ProThin project

Etteplan Oyj, press release, 10 May 2022 9 am EEST Etteplan’s additive manufacturing expertise is playing a crucial role in an ongoing additive manufacturing (AM) project of the Swedish strategic innovation program Produktion2030. The ProThin project aims at discovering how to produce components with thin walls and narrow channels with the AM technology Laser Powder Bed Fusion (LPBF). Etteplan is in the forefront of the ProThin project, part of the Swedish strategic innovation program Produktion2030. The goal is to enable production of thin walls and narrow channels with Laser Powder

Gaming Innovation Group reports Q1 2022

Gaming Innovation Group Inc. (GiG) reports Q1 2022 revenues* of €19.1 million and an EBITDA of €6.5 million.  “I am satisfied with the Company’s progress in the first quarter, and we now move toward an exciting second quarter where our global strategic position across multiple areas of high value within the iGaming industry creates truly exciting prospects for growth across the business units”, says Richard Brown, CEO of GiG.  Financial Highlights · GiG achieved all time high revenues* in Q1 2022 of €19.1m (15.0), an increase of 27% YoY, all organic growth  · EBITDA was €6.5m (

Katarina Gabrielson appointed as CEO of Oriola

Oriola Corporation Insider information 10 May 2022 at 9:00 a.m. Katarina Gabrielson appointed as CEO of Oriola Oriola Corporation’s Board of Directors has appointed Ms. Katarina Gabrielson (M.Sc., Swedish citizen) as CEO starting from 10 May 2022. Katarina Gabrielson is currently working as interim CEO and Vice President of the company’s B2B business in Sweden. She has been working in various Director positions at Oriola since 2012. “The Board of Directors commenced the recruitment process immediately after Elisa Markula’s resignation in February 2022. After careful evaluation, I

Proact enhances networking services offering with software-defined managed services package “SD-Connect”

By adding SD-Connect – comprised of SD-WAN, SD-WiFi and SD-LAN – to its portfolio, Europe’s leading independent data centre and cloud services provider Proact is able to offer its customers an AI-driven networking solution. The improved network performance made possible by these services is critical for enabling access to data wherever it is stored.The services that make up SD-Connect are designed to interoperate with one another to ensure ideal network coverage. They are additionally delivered from the same vendor, resulting in a more consistent service than a mixture of networking

Relais Group Plc: Increase in the number of shares registered in the trade register

Relais Group Plc, Company Release 10 May 2022 at 9.00 a.m. EET In order to meet the terms and conditions related to the acquisition of Lumise Oy completed on 31 March 2021, Relais Group Plc issued a total of 64,407 new shares on 25 April 2022 in a directed free share issue. The shares have been entered in the Finnish Trade Register on 10 May 2022. The new shares will carry the right to receive dividends and other distribution of funds, if any, and other shareholder rights in Relais Group Plc as of the registration of the shares in the Finnish Trade Register. Relais Group Plc now has a

Veg of Lund AB: Interim Report January - March 2022

Proactive efforts to drive salesJanuary–March 2022 · Net sales amounted to TSEK 455 (84). · Operating profit before depreciation and amortization (EBITDA) amounted to TSEK -17 712 (-2,164), and EBIT amounted to TSEK -17,764 (-2,282). · Net profit amounted to TSEK -17,999 (-2,270). Significant events January–March 2022 · An extraordinary general meeting held on 31 January 2022 elected two new members to the Board of Directors: Magnus Nordin and Håkan K Pålsson. Håkan K Pålsson was elected Chairman of the Board. · UK food companies choose DUG[®] for vegetarian and vegan

SciBase to present at the Redeye Medtech & Diagnostics Seminar on May 11, 2022

SciBase a leading developer of augmented intelligence-based solutions for skin disorders, announced today that CEO Simon Grant will present an update on the latest developments from SciBase at the Redeye Medtech & Diagnostics seminar on May 11[th] at 10.55 pm. The presentation will be followed by a short Q&A. The presentations are live broadcasted at https://www.redeye.se/events/825143/redeye-theme-medtech-diagnostics . The presentation will also be available at www.redeye.se and on the Company's website i n Redeye Universe.“It has been a busy start to the year and we see an exciting year

Saga Pure: First quarter 2022 financial results

(Oslo, 10 May 2022) Saga Pure ASA (Saga Pure, OSE: SAGA) reported a net profit in the first quarter 2022 of NOK 53.6 million (Q1 2021: NOK 147.8 million), corresponding to a year-to-date return on equity of 5 percent.“During the first quarter of 2022, we have witnessed volatile markets. We thus continue to be selective in our investment approach and focus on further developing the companies in our portfolio. We still have strong conviction of our portfolio companies, supported by our increased exposure in Bergen Carbon Solutions and Horisont Energi during the quarter. We hold a significant

Rapid sales growth and a strong start to the year

First quarter 2022 · Net revenue increased by 65% to SEK 756 million (457). Organic growth was 7%. · Adjusted EBITA increased to SEK 88 million (73), corresponding to a margin of 11.6% (15.9). · Profit for the period totalled SEK 33 million (32) and earnings per share, basic and diluted, amounted to SEK 0.24 (1.29). · Adjusted earnings per share, basic and diluted, totalled SEK 0.32 (1.40). · Cash flow from operating activities amounted to SEK 76 million (111). · On 1 January, the acquisitions were completed of German company Zentrale Autoglas GmbH, which operates a bus

There are no items matching the current filter
There are no more items matching the current filter
Back to top